|
KMID : 0380020200350020095
|
|
Korean Journal of Biotechnology and Bioengineering
2020 Volume.35 No. 2 p.95 ~ p.104
|
|
|
CAR-T Therapy Targeting Solid Tumor
|
|
Kwon Mi-Ji
Park Hee-Ho
|
|
|
Abstract
|
|
|
|
The chimeric antigen receptor (CAR) is a receptor that introduces the specificity of the immune cell to the tumor. CAR was first developed in the mid-1980s. CARs have evolved from first-generation CARs to fourth-generation CARs. Generally, CAR-T is made by separating and activating T cells from the patient’s blood and then using virus vectors to form CARs. CAR-T has successful clinical results in the treatment of hematologic malignancies, and there are U.S. FDA-approved drugs. Although solid tumor research is being actively conducted, the results of clinical trials on solid tumor are still not as expected. Therefore, it is necessary to study CAR-T therapy, especially efficacy and stability of CAR-T cells against solid tumors.
|
|
|
KEYWORD
|
|
|
chimeric antigen receptor (CAR), CAR-T cell, hematologic malignancy, solid tumor, clinical trial
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|